Guardant Health, Inc. Common Stock earnings per share and revenue
On 29 de out. de 2025, GH reported earnings of -0.74 USD per share (EPS) for Q3 25, missing the estimate of -0.72 USD, resulting in a -2.27% surprise. Revenue reached 265.20 milhão, compared to an expected 242.76 milhão, with a 9.24% difference. The market reacted with a +27.87% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analistas forecast an EPS of -0.68 USD, with revenue projected to reach 275.85 milhão USD, implying an diminuir of -8.11% EPS, and aumentar of 4.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Guardant Health, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Guardant Health, Inc. Common Stock reported EPS of -$0.74, missing estimates by -2.27%, and revenue of $265.20M, 9.24% above expectations.
How did the market react to Guardant Health, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 27.87%, changed from $72.27 before the earnings release to $92.41 the day after.
When is Guardant Health, Inc. Common Stock expected to report next?
The next earning report is scheduled for 18 de fev. de 2026.
What are the forecasts for Guardant Health, Inc. Common Stock's next earnings report?
Based on 25
analistas, Guardant Health, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $275.85M for Q4 2025.